McKesson Corporation $MCK Shares Sold by BNP Paribas

BNP Paribas reduced its holdings in McKesson Corporation (NYSE:MCK) by 3.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,667 shares of the company’s stock after selling 1,592 shares during the period. McKesson makes up 1.2% of BNP Paribas’ holdings, making the stock its 21st biggest position. BNP Paribas’ holdings in McKesson were worth $39,590,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. J.W. Cole Advisors Inc. raised its holdings in shares of McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after acquiring an additional 1,329 shares during the period. Private Wealth Partners LLC raised its stake in shares of McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after acquiring an additional 1,682 shares during the period. AlphaQuest LLC lifted its stake in McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after purchasing an additional 843 shares in the last quarter. CW Advisors LLC lifted its stake in McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after acquiring an additional 8,130 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of McKesson by 12.4% during the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after purchasing an additional 36,451 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Trading Down 0.3%

Shares of McKesson stock opened at $941.51 on Friday. The company has a 50-day moving average of $893.90 and a two-hundred day moving average of $825.35. The stock has a market cap of $115.32 billion, a PE ratio of 27.08, a price-to-earnings-growth ratio of 1.51 and a beta of 0.38. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The company had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.McKesson’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, sell-side analysts forecast that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s payout ratio is currently 9.43%.

Analyst Ratings Changes

MCK has been the subject of a number of recent research reports. Raymond James Financial set a $970.00 target price on McKesson in a report on Thursday, March 5th. Wells Fargo & Company upped their target price on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a report on Thursday, February 5th. Zacks Research downgraded McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Leerink Partners restated an “outperform” rating and issued a $1,085.00 price objective on shares of McKesson in a research note on Thursday, March 5th. Finally, Mizuho boosted their target price on McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a report on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $960.93.

Insider Buying and Selling

In other news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michele Lau sold 2,725 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the completion of the transaction, the executive vice president directly owned 3,247 shares of the company’s stock, valued at $3,214,530. The trade was a 45.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 3,868 shares of company stock valued at $3,743,820. Company insiders own 0.08% of the company’s stock.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.